GYRE (Gyre Therapeutics) Other Stockholders Equity : $-0.0 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Other Stockholders Equity?

Gyre Therapeutics's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $-0.0 Mil.

Gyre Therapeutics's quarterly Other Stockholders Equity increased from Jun. 2024 ($-0.0 Mil) to Sep. 2024 ($0.0 Mil) but then declined from Sep. 2024 ($0.0 Mil) to Dec. 2024 ($-0.0 Mil).

Gyre Therapeutics's annual Other Stockholders Equity increased from Dec. 2022 ($-0.0 Mil) to Dec. 2023 ($-0.0 Mil) but then declined from Dec. 2023 ($-0.0 Mil) to Dec. 2024 ($-0.0 Mil).

Gyre Therapeutics Other Stockholders Equity Historical Data

The historical data trend for Gyre Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Other Stockholders Equity Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Other Stockholders Equity

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial						-	-	-	-	-

Gyre Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Gyre Therapeutics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.